BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rcadia's COR Analyzer(R) System Receives CE Mark


3/8/2010 10:37:30 AM

NEWTON, Mass., March 8 /PRNewswire/ -- Rcadia Medical Imaging today announced that it has received a CE Mark for the COR Analyzer(R) System, its proprietary software that helps identify patients with significant CAD (Coronary Artery Disease) by a fully automatic analysis of coronary CT angiography (cCTA) studies. The CE Mark allows the company to market the system in the European Union and other countries that accept the CE Mark registration. The COR Analyzer is marketed in the U.S. under 510(k) clearance and Rcadia was named 2009 Best New Radiology Vendor by AuntMinnie.com.

"The CE mark is an important milestone in Rcadia's program to advance the practical application of coronary CT angiography," said Shai Levanon, President and CEO of Rcadia. "The COR Analyzer is a powerful, time and cost-effective tool to support clinical decision making. The system's real time coronary artery analysis has demonstrated great potential in emergency department triage to help rule out coronary artery disease in chest pain patients, reducing unnecessary hospitalizations and improving patient care. The COR Analyzer is also designed to optimize workflow in cardiology and radiology departments."

In numerous clinical studies to date as well as in routine clinical use, the COR Analyzer System has demonstrated high negative predictive value (over 95 percent). In a recent analysis of cCTA images from low to moderate risk emergency department patients with chest pain, presented at the Radiological Society of North America annual meeting, the COR Analyzer yielded a negative predictive value (NPV) of 98 percent compared with expert readers.

About Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer(R) System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting coronary artery disease. The COR Analyzer improves the utility of Coronary CTA studies in the emergency department to triage chest pain patients and optimizes workflow in cardiology and radiology departments. Learn more at www.rcadia.com.

CONTACT: Peter Steinerman of Steinerman Biomedical for Rcadia Medical
Imaging, +1-516-374-3031

Web site: http://www.rcadia.com/



Read at BioSpace.com

Rcadia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES